4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

3 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

S-1 - Tivic Health Systems, Inc. (0001787740) (Filer)

DEF 14A - Tivic Health Systems, Inc. (0001787740) (Filer)

PRE 14A - Tivic Health Systems, Inc. (0001787740) (Filer)

8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

10-Q - Tivic Health Systems, Inc. (0001787740) (Filer)

8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

Breakthrough Findings to be Reported Later this Year and Applied to Upcoming Phase I Clinical Trial Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company developing treatments that stimulate immune pathways to treat disease, today announced it has completed all study visits in the Optimization Study for its patent pending, non-invasive cervical vagus nerve stimulation (ncVNS) device. Initial findings reinforce the importance of personalization for therapeutic efficacy. Tivic expects to release the study results later this year. The study was conducted by The Feinstein Institute of Bioelectronic Medicine with the objective of identifying device parameters th

Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today its Virtual Annual General Meeting of Shareholders will be held on Monday, June 30, 2025 at 1:00 PM, Pacific Time | 4:00 PM Eastern Time. The Company has adopted a virtual format for its Annual Meeting to provide a consistent and convenient experience for all stockholders regardless of their location. In lieu of a live Q&A session, stockholders can submit questions for management's consideration through the virtual Annual Meeting platform both before and during the Annual Meeting. WHEN: Monday, June 30, 2025 TIME: 1:00 PM PT | 4:00 PM ET WHERE: w

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and 12th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through June 17. June 11th PresentationTicker(s)Nika Pharmaceuticals(OTCQB:NIKA)Tivic Health Systems Inc.(NASDAQ:TIVC)Ad

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management. "The life sciences sector is driving breakthrough innovation, and we're proud to give these pioneering co

Pre-recorded Conference Call to Follow at 1:30 p.m. PDT/4:30 p.m. EDT Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced financial results for the first quarter ended March 31, 2025 and outlined operational highlights based on its newly expanded clinical pipeline. "This is a defining time for the company. During the quarter we initiated a significant strategic shift, dramatically expanding Tivic's clinical pipeline for restoring immune system health," stated Tivic CEO Jennifer Ernst. "In February, we executed a comprehensive worldwide exclusive licensing agreement for the Phase III TLR5 agonist, Entolimod and its molecular derivative, Ent

Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food & Drug Administration. Scorpius BioManufacturing, Inc. is an integrated contract development and manufacturing organization (CDMO) and subsidiary of Scorpius Holdings Inc. (OTC:SCPX), which will be the primary U.S. manufacturer for Entolimod™. Scorpius plans to utilize its scientific and tec

- New patent protects methods for increasing efficacy via personalization of stimulation parameters and electrode positioning - Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today it is expanding its non-invasive VNS patent portfolio with the filing of a new patent application with the United States Patent and Trademark Office. Patent No. 63,801,058 entitled "Vagus Nerve Stimulation System" expands the claims and protection around the technology that Tivic is developing and which it expects will redefine state-of-the art in non-invasive vagus nerve stimulation. "We continue to build a defensible position for our next generation VNS technology," s

Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its first quarter results for 2025 via pre-recorded conference call and webcast on Thursday, May 15, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 1-877-407-0779 International: 1-201-389-0914 Conference ID: 13753498 Webcast Link https://viavid.webcasts.com/starthere.jsp?ei=1717125&tp_key=322c3ca4f6 About Tivic Health Systems, Inc. Tivic Health is a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight

Senior Level Meetings Included Discussion of Tivic's TLR5 and Vagus Nerve Stimulation Programs Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today that it provided briefings to senior leadership at the White House and FDA which garnered significant positive interest in potential military and defense applications for its biologic and bioelectronic product candidates. Both meetings were held in Washington, D.C. on April 17th. The U.S. Government, through agencies including BARDA, NASA, Defense Threats Reduction Agency, Department of the Army, and the Department of Defense, has previously provided significant funding to the development of Tivic's TL

Tivic Health Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, today announced that, on March 28, 2025, it exercised its licensing option for the exclusive, worldwide rights to advance Entolimod™ for a second indication, Neutropenia. This expansion of commercial rights is part of the license agreement with Statera Biopharma for its late-stage Toll-like Receptor 5 (TLR5) immunotherapy program Entolimod™. Neutropenia is a condition characterized by lower-than-normal levels of neutrophils, a type of white blood cell essential for combating infections. Causes of neutropenia include chemotherapy and radiation treatments, chronic infection, autoimmune diseases, bone marrow disorde

Handley Joins as President of Tivic Biopharma and Chief Operating Officer of Tivic Health Following Its Licensing of Strategic Biopharma Assets From Statera Biopharma Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today that Michael K. Handley, formerly Chief Executive Officer, President and Chairman of Statera Biopharma, Inc., has joined Tivic Health as the President of Tivic Biopharma, a newly formed division of Tivic Health. Additionally, he will assume the role of Chief Operating Officer of Tivic Health and will work closely with the CEO and other leadership team members to develop and operationalize company-wide strategies. His key responsi

Kimberly Bambach, Ms. Wolf's predecessor, continues with Tivic as advisor focused on strategic transactions and special projects Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to announce the appointment of Lisa Wolf as Interim Chief Financial Officer (CFO) of the company, effective October 1, 2024. Ms. Wolf will take over from Kimberly Bambach, who has served as the company's interim CFO since April 2023. Ms. Bambach will continue with Tivic in an advisory role for strategic transactions and other special projects. "Lisa has served as a senior member of Tivic's finance team for over two

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the appointment of veteran Kimberly Bambach to serve as Interim Chief Financial Officer of the company and the engagement of Christina Valauri as a strategic advisor to the Board of Directors. These additions aim to strengthen the company's financial foundation and bring growth and M&A expertise to the team. Ms. Bambach brings over 30 years of financial leadership experience in both public and private companies across industries. Her background includes financial leadership in medical and retail markets, manufacturing, wholesale distrib

Pre-recorded Conference Call to Follow at 1:30 p.m. PDT/4:30 p.m. EDT Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced financial results for the first quarter ended March 31, 2025 and outlined operational highlights based on its newly expanded clinical pipeline. "This is a defining time for the company. During the quarter we initiated a significant strategic shift, dramatically expanding Tivic's clinical pipeline for restoring immune system health," stated Tivic CEO Jennifer Ernst. "In February, we executed a comprehensive worldwide exclusive licensing agreement for the Phase III TLR5 agonist, Entolimod and its molecular derivative, Ent

Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its first quarter results for 2025 via pre-recorded conference call and webcast on Thursday, May 15, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 1-877-407-0779 International: 1-201-389-0914 Conference ID: 13753498 Webcast Link https://viavid.webcasts.com/starthere.jsp?ei=1717125&tp_key=322c3ca4f6 About Tivic Health Systems, Inc. Tivic Health is a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight

Pre-recorded Conference Call and Webcast to Follow Today at 1:30 PM PDT / 4:30 PM EDT Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, today announced year end December 31, 2024 financial results, highlighted key developments in its clinical program expansion and discussed progress made across the company's operations. "The important strategic events of the past several months have been nothing short of transformative," stated Tivic Health Chief Executive Officer, Jennifer Ernst. "We have successfully reshaped the company by expanding Tivic's opportunities in the biotech sector by in-licensing a late-stage biologic immunotherapy and advancing our ongoing work

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its year-end financial results for 2024 via pre-recorded conference call and webcast on Friday, March 21, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 1-877-407-0779 International: 1-201-389-0914 Conference ID Code: 13752399 Webcast Link https://viavid.webcasts.com/starthere.jsp?ei=1711877&tp_key=ce7eaa5c39 About Tivic Health Systems, Inc. Tivic Health is a diversified therapeutics company harnessing the power of the immune and autonom

Broad licensing agreement accelerates Tivic's transformation into a diversified therapeutics company, adds late-stage immunotherapeutic to clinical pipeline. Potential for FDA approval within 24 months. Tivic Health Systems, Inc., (NASDAQ:TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC:STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement establishes Tivic as a diversified t

Pre-recorded Conference Call to Follow at 1:30 p.m. PDT/4:30 p.m EDT Tivic Health® Systems, Inc. (NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced third quarter and nine-months ended September, 30, 2024 financial results and discussed growth strategies based on its novel, patent-pending vagus nerve stimulation (VNS) science and device technology. "This quarter we made significant progress on each of the three prongs of our strategy for delivering shareholder value," stated Jennifer Ernst, CEO of Tivic Health. "The first prong is the aggressive steps we have taken to improve the economics of the ClearUP product line -- our comme

– Conference Call and Webcast to Follow at 1:30 p.m. PST/4:30 p.m. EST - Tivic Health® Systems, Inc. (NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it will report financial results on Thursday, November 14 after market close. The release will be followed by a pre-recorded conference call and webcast at 1:30 p.m. PST / 4:30 p.m. EST. Shareholders, interested parties, and prospective investors are invited to join via dial in or webcast. The company invites questions to be submitted to [email protected] by November 11. Conference Call Details: Toll Free: 877-545-0523 International: 973-528-0016 Access Code: 507355 Webcast Link

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its Q2 2024 financial results and a corporate update via pre-recorded conference call and webcast on Wednesday, August 14 at 1:30 PM PT / 4:30 PM ET. Current shareholders, interested individuals and future investors are encouraged to join the webcast to hear the company executives provide a corporate update that will highlight the importance of Tivic's vagus nerve research program and its market potential. The company invites questions to be submitted to [email protected] by August 11, 2024. Teleconference Details:

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its Q1 2024 financial results via pre-recorded conference call and webcast on Wednesday, May 15th at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 877-545-0523 International: 973-528-0016 Participant Access Code: 464810 Webcast Link https://www.webcaster4.com/Webcast/Page/2865/50489 About Tivic Tivic is a commercial health tech company advancing the field of bioelectronic medicine. Tivic's patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures

Tivic Health® Systems, Inc. ("Tivic Health") (NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its year-end financial results for 2023 via pre-recorded conference call and webcast on Monday, March 25, 2024 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 434944 Webcast Link https://www.webcaster4.com/Webcast/Page/2865/50026 About Tivic Tivic is a commercial health tech company advancing the field of bioelectronic medicine. Tivic's patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus

SC 13G - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G/A - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G/A - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G/A - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G - Tivic Health Systems, Inc. (0001787740) (Subject)